Shalata, W.; Naamneh, R.; Najjar, W.; Abu Amna, M.; Asla, M.; Agbarya, A.; Brenner, R.; Abu Jama, A.; Abu Yasin, N.; Abu Juda, M.;
et al. Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases. Med. Sci. 2025, 13, 200.
https://doi.org/10.3390/medsci13030200
AMA Style
Shalata W, Naamneh R, Najjar W, Abu Amna M, Asla M, Agbarya A, Brenner R, Abu Jama A, Abu Yasin N, Abu Juda M,
et al. Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases. Medical Sciences. 2025; 13(3):200.
https://doi.org/10.3390/medsci13030200
Chicago/Turabian Style
Shalata, Walid, Rashad Naamneh, Wenad Najjar, Mahmoud Abu Amna, Mohnnad Asla, Abed Agbarya, Ronen Brenner, Ashraf Abu Jama, Nashat Abu Yasin, Mhammad Abu Juda,
and et al. 2025. "Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases" Medical Sciences 13, no. 3: 200.
https://doi.org/10.3390/medsci13030200
APA Style
Shalata, W., Naamneh, R., Najjar, W., Abu Amna, M., Asla, M., Agbarya, A., Brenner, R., Abu Jama, A., Abu Yasin, N., Abu Juda, M., Abu Zeid, E. E. D., Rouvinov, K., & Yakobson, A.
(2025). Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases. Medical Sciences, 13(3), 200.
https://doi.org/10.3390/medsci13030200
